HIV can evolve to evade the long-acting antiretroviral, but such mutations impair its ability to replicate efficiently.
POZ news story
HIV can develop capsid mutations that confer resistance to lenacapavir, but doing so can come at a cost to viral fitness, according to a study results published in Science Translational Medicine. These findings have implications for lenacapavir use for HIV treatment and pre-exposure prophylaxis (PrEP).
“As [lenacapavir] moves into broader use for both PrEP and treatment, these findings highlight the importance of maintaining fully active companion drugs during HIV treatment, improving access to resistance testing and surveillance, and accelerating development of next-generation capsid inhibitors,” Manish Choudhary, PhD, and Jonathan Li, MD, of Brigham and Women’s Hospital and Harvard Medical School, wrote in an accompanying commentary.
Read the full news story here.
Source : POZ
Related HIV and Co-Infections News
-
[Open letter] Civil society demands access strategy for Merck’s promising long-acting HIV prevention pill covering all LMICs
-
[Press release] Queen Mary University of London: First of its kind daily HIV treatment shows promising results
-
aidsmap: Immigration and poverty tied to heightened HIV risk in the Netherlands
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.